FDA Approves 150-mg Doryx Tabs
The FDA has approved Warner Chilcott’s 150-mg strength Doryx delayed-release tablets to treat acne.
The company already offers Doryx (doxycycline hyclate), a tetracycline-class oral antibiotic for treatment of severe acne, in 75-mg and 100-mg strengths.
Doryx delayed-release tablets contain enteric-coated pellets of doxycycline hyclate, which do not release until they reach the small intestine, minimizing the gastrointestinal side effects associated with other doxycycline products.
Doryx, which competes with Pfizer’s Vibramycin (doxycycline) and other treatments, had revenue of $116 million in 2007, according to Warner Chilcott.